Prelude Therapeutics (PRLD) Capital Expenditures (QoQ) (2020 - 2025)
Powered by 
Analysis
Prelude Therapeutics (PRLD) Capital Expenditures (QoQ) (2020 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Prelude Therapeutics | 540.15 Mn | 259.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -57.45% |
| Mar 31, 2025 | -11.32% |
| Dec 31, 2024 | -15.87% |
| Sep 30, 2024 | -82.45% |
| Jun 30, 2024 | 24.22% |
| Mar 31, 2024 | -74.40% |
| Dec 31, 2023 | 91.03% |
| Sep 30, 2023 | -39.88% |
| Jun 30, 2023 | 21.36% |
| Mar 31, 2023 | 106.11% |
| Dec 31, 2022 | -57.10% |
| Sep 30, 2022 | 20.84% |
| Jun 30, 2022 | -20.38% |
| Mar 31, 2022 | 220.54% |
| Dec 31, 2021 | -54.93% |
| Sep 30, 2021 | 72.97% |
| Jun 30, 2021 | -61.36% |
| Mar 31, 2021 | 108.46% |
| Dec 31, 2020 | 178.24% |
| Sep 30, 2020 | 304.76% |